In our study, the risk of malignancy was found in patients over 65 years of age, and the combination of anti-TIF1ɣ + anti-Mi2α autoantibodies was reported in a patient with small cell carcinoma of the lung. Here, TRIM24 is linked to small cell lung carcinoma.